AR066843A2 - Formulacion galenica administrable por via oral que permite una absorcion mejorada de principios activos, uso de un agente mejorador de la absorcion para preparar una forma de dosificacion administrable por via oral y procedimiento para preparar dicha formulacion galenica - Google Patents
Formulacion galenica administrable por via oral que permite una absorcion mejorada de principios activos, uso de un agente mejorador de la absorcion para preparar una forma de dosificacion administrable por via oral y procedimiento para preparar dicha formulacion galenicaInfo
- Publication number
- AR066843A2 AR066843A2 ARP080102354A ARP080102354A AR066843A2 AR 066843 A2 AR066843 A2 AR 066843A2 AR P080102354 A ARP080102354 A AR P080102354A AR P080102354 A ARP080102354 A AR P080102354A AR 066843 A2 AR066843 A2 AR 066843A2
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- administrable
- absorption
- galenic formulation
- oral
- Prior art date
Links
- 238000010521 absorption reaction Methods 0.000 title abstract 5
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 2
- 239000000203 mixture Substances 0.000 title 2
- 239000013061 administrable dose form Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 4
- 229930195729 fatty acid Natural products 0.000 abstract 4
- 239000000194 fatty acid Substances 0.000 abstract 4
- 150000004665 fatty acids Chemical class 0.000 abstract 4
- -1 polyoxyethylene Polymers 0.000 abstract 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 229920005862 polyol Polymers 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000005215 alkyl ethers Chemical class 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 150000002191 fatty alcohols Chemical class 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 229940068965 polysorbates Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Addiction (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Forma galénica administrable por vía oral que permite una absorcion mejorada a través de la membrana o por vía paracelular a nivel del tracto gastrointestinal, de un principio activo, que comprende metformina o una de sus sales farmacéuticamente aceptables, especialmente hidrocloruro; un agente promotor de absorcion que tenga un valor del balance hidrofilo-lipofilo (HLB) mayor que 8, estando constituido dicho agente promotor de absorcion por una o varias sustancias lipídicas elegidas entre polisorbatos; éteres de polioxietileno y alquilo; ésteres de polioxietileno y ácidos grasos; ácidos grasos; alcoholes grasos; ácidos biliares y sus sales de cationes aceptables desde el punto de vista farmacéutico; ésteres de alcanoles C1-6 con ácidos grasos; ésteres de polioles con ácidos grasos, en los que el poliol tiene de 2 a 6 funciones hidroxilo, y glicéridos poliglicolizados, junto con uno o varios excipientes farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9802143A FR2775188B1 (fr) | 1998-02-23 | 1998-02-23 | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066843A2 true AR066843A2 (es) | 2009-09-16 |
Family
ID=9523244
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100731A AR018109A1 (es) | 1998-02-23 | 1999-02-23 | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA |
| ARP080102354A AR066843A2 (es) | 1998-02-23 | 2008-06-04 | Formulacion galenica administrable por via oral que permite una absorcion mejorada de principios activos, uso de un agente mejorador de la absorcion para preparar una forma de dosificacion administrable por via oral y procedimiento para preparar dicha formulacion galenica |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100731A AR018109A1 (es) | 1998-02-23 | 1999-02-23 | FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6426087B1 (es) |
| EP (2) | EP1056445B1 (es) |
| JP (1) | JP4828020B2 (es) |
| KR (1) | KR100587181B1 (es) |
| CN (1) | CN1182837C (es) |
| AP (1) | AP2000001943A0 (es) |
| AR (2) | AR018109A1 (es) |
| AT (2) | ATE268164T1 (es) |
| AU (1) | AU750785B2 (es) |
| BR (1) | BR9908121A (es) |
| CA (1) | CA2321267C (es) |
| CZ (1) | CZ299366B6 (es) |
| DE (2) | DE69939605D1 (es) |
| DK (2) | DK1410791T3 (es) |
| ES (2) | ES2222695T3 (es) |
| FR (1) | FR2775188B1 (es) |
| HU (1) | HU226732B1 (es) |
| ID (1) | ID26022A (es) |
| NO (1) | NO20004190L (es) |
| OA (1) | OA11454A (es) |
| PL (2) | PL191415B1 (es) |
| PT (2) | PT1410791E (es) |
| RU (1) | RU2228201C2 (es) |
| SI (2) | SI1410791T1 (es) |
| SK (2) | SK285188B6 (es) |
| WO (1) | WO1999042086A1 (es) |
| ZA (1) | ZA991408B (es) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
| DE10026699A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| SE0200475D0 (sv) * | 2002-02-15 | 2002-02-15 | Ltp Lipid Technologies Provide | Oral farmaceutisk beredning |
| EP1499306A4 (en) | 2002-04-12 | 2007-03-28 | Merck & Co Inc | BICYCLIC AMIDE |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| FR2845289B1 (fr) * | 2002-10-04 | 2004-12-03 | Ethypharm Sa | Spheroides, procede de preparation et compositions pharmaceutiques. |
| AU2003282498A1 (en) * | 2002-10-07 | 2004-05-04 | Chiron Corporation | Hiv vaccine formulations |
| US20040151769A1 (en) * | 2002-12-31 | 2004-08-05 | Boehringer Ingelheim International Gmbh | Film coated tablet containing an extract of red vine leaves |
| ITRM20030074A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Formulazioni semisolide a rilascio immediato intese |
| US20040241252A1 (en) * | 2003-05-29 | 2004-12-02 | Abney Christopher Charles | Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same |
| RU2241449C1 (ru) * | 2003-09-25 | 2004-12-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция для лечения диабета (варианты) |
| WO2005060942A1 (en) * | 2003-12-19 | 2005-07-07 | Aurobindo Pharma Ltd | Extended release pharmaceutical composition of metformin |
| BRPI0510074A (pt) * | 2004-04-22 | 2007-10-16 | Boehringer Ingelheim Int | composições farmacêuticas para o tratamento de distúrbios sexuais ii |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| US20080181946A1 (en) * | 2004-05-14 | 2008-07-31 | Braj Bhushan Lohray | Controlled Release Delivery System For Metformin |
| EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
| US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
| CA2576812A1 (en) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
| WO2006038134A1 (en) * | 2004-10-01 | 2006-04-13 | Firmenich Sa | Perfuming or flavouring microcapsules comprising an explosion suppressant |
| EP1858515A2 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| JP2008538741A (ja) * | 2005-03-04 | 2008-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鬱病の治療用及び／又は予防用の医薬組成物 |
| UY29445A1 (es) * | 2005-03-30 | 2006-10-02 | Generex Pharm Inc | Composiciones para la transmisión transmucosa oral de la metformina |
| JP2008540356A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬物乱用の治療方法 |
| CA2608363A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
| EP1888070A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of sexual dysfunctions due to medical conditions |
| KR101306088B1 (ko) * | 2005-06-21 | 2013-09-09 | 메르크 파텐트 게엠베하 | (ｒ)-(-)-２-[５-(４-플루오로페닐)-３-피리딜-메틸아미노메틸]크로만을 함유하는 고형 약제학적 조성물 |
| EP1745788A1 (de) * | 2005-07-22 | 2007-01-24 | KTB Tumorforschungsgesellschaft mbH | Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie |
| JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| JP2009513604A (ja) * | 2005-10-29 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| WO2007106957A1 (en) * | 2006-03-21 | 2007-09-27 | Laboratoires Smb S.A. | Multiple units controlled-release floating dosage forms |
| KR20090005371A (ko) * | 2006-05-09 | 2009-01-13 | 베링거 인겔하임 인터내셔날 게엠베하 | 폐경후 성욕 장애의 치료를 위한 플리반세린의 용도 |
| WO2008000760A1 (en) | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
| CA2657043A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
| MX2009001551A (es) * | 2006-08-14 | 2009-02-20 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas. |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| WO2008022932A2 (en) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
| US20080078498A1 (en) * | 2006-10-03 | 2008-04-03 | Zeik Douglas B | Articles and methods for applying color on surfaces |
| EP1952803A1 (en) | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
| WO2009033079A1 (en) * | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| TW200924746A (en) * | 2007-09-07 | 2009-06-16 | Xenoport Inc | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| UY31335A1 (es) * | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
| EP2042165A1 (de) * | 2007-09-28 | 2009-04-01 | Swiss Caps Rechte und Lizenzen AG | Hot-Melt-Befüllte Weichkapseln |
| TW200932734A (en) * | 2007-10-15 | 2009-08-01 | Xenoport Inc | Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| CA2638240C (en) * | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
| EP2370060B1 (en) | 2008-11-27 | 2017-05-03 | B.R.A.I.N. Biotechnology Research and Information Network AG | Hydrophobins as surface active proteins as excipients in solid pharmaceutical formulations |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| EP2512455B8 (en) | 2009-12-18 | 2014-07-23 | FrieslandCampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
| JP5546900B2 (ja) * | 2010-02-25 | 2014-07-09 | ライオン株式会社 | パナキサトリオール安定化組成物 |
| HK1199841A1 (en) * | 2010-05-18 | 2015-07-24 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| EP2621487B1 (en) * | 2010-09-28 | 2017-05-03 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| US20130143867A1 (en) * | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| KR20180021932A (ko) * | 2013-03-15 | 2018-03-05 | 아이슈티카 인코포레이티드 | 아비라테론 아세테이트 제제 |
| US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
| CA2914365C (en) | 2013-06-05 | 2022-03-15 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
| US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
| US12042566B2 (en) | 2017-05-17 | 2024-07-23 | Confluence Pharmaceuticals, Llc | Formulations of homotaurines and salts thereof |
| US20240350414A1 (en) | 2021-08-25 | 2024-10-24 | Basf Se | Direct tableting auxiliary composition |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI63335B (fi) * | 1979-02-02 | 1983-02-28 | Orion Yhtymae Oy | Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne |
| FR2457281A1 (fr) * | 1979-05-23 | 1980-12-19 | Meram Lab | Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee |
| GB8524421D0 (en) * | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
| JPS62265226A (ja) * | 1986-05-12 | 1987-11-18 | Fujisawa Pharmaceut Co Ltd | 経口投与用製剤 |
| ZA898331B (en) * | 1988-11-22 | 1990-07-25 | Hoffmann La Roche | Pharmaceutical compositions |
| US5190748A (en) * | 1988-11-22 | 1993-03-02 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
| US5139786A (en) * | 1989-07-07 | 1992-08-18 | Ciba-Geigy Corporation | Topical formulations |
| JPH03275633A (ja) * | 1990-03-23 | 1991-12-06 | Teikoku Seiyaku Co Ltd | 生理活性ポリペプチドの吸収促進剤 |
| US5138786A (en) | 1991-07-17 | 1992-08-18 | Fischer Michael G | Insta-guard firearm protection |
| IT1255895B (it) * | 1992-10-20 | 1995-11-17 | Laura Chiodini | Composizioni farmaceutiche contenenti una calcitonina |
| DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
| US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
| JP3275633B2 (ja) | 1995-06-16 | 2002-04-15 | 松下電器産業株式会社 | 脱水兼用洗濯機 |
| GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
-
1998
- 1998-02-23 FR FR9802143A patent/FR2775188B1/fr not_active Expired - Fee Related
-
1999
- 1999-02-16 EP EP99913165A patent/EP1056445B1/en not_active Expired - Lifetime
- 1999-02-16 ES ES99913165T patent/ES2222695T3/es not_active Expired - Lifetime
- 1999-02-16 SI SI9931019T patent/SI1410791T1/sl unknown
- 1999-02-16 JP JP2000532103A patent/JP4828020B2/ja not_active Expired - Fee Related
- 1999-02-16 CN CNB998032182A patent/CN1182837C/zh not_active Expired - Fee Related
- 1999-02-16 PL PL342162A patent/PL191415B1/pl unknown
- 1999-02-16 WO PCT/EP1999/000994 patent/WO1999042086A1/en not_active Ceased
- 1999-02-16 CA CA002321267A patent/CA2321267C/en not_active Expired - Fee Related
- 1999-02-16 ES ES04001294T patent/ES2314302T3/es not_active Expired - Lifetime
- 1999-02-16 RU RU2000124535/15A patent/RU2228201C2/ru not_active IP Right Cessation
- 1999-02-16 BR BR9908121-0A patent/BR9908121A/pt not_active Application Discontinuation
- 1999-02-16 DK DK04001294T patent/DK1410791T3/da active
- 1999-02-16 AP APAP/P/2000/001943A patent/AP2000001943A0/en unknown
- 1999-02-16 SK SK1255-2000A patent/SK285188B6/sk not_active IP Right Cessation
- 1999-02-16 DK DK99913165T patent/DK1056445T3/da active
- 1999-02-16 PT PT04001294T patent/PT1410791E/pt unknown
- 1999-02-16 AT AT99913165T patent/ATE268164T1/de active
- 1999-02-16 AT AT04001294T patent/ATE408399T1/de active
- 1999-02-16 EP EP04001294A patent/EP1410791B1/en not_active Expired - Lifetime
- 1999-02-16 AU AU31408/99A patent/AU750785B2/en not_active Ceased
- 1999-02-16 KR KR1020007009307A patent/KR100587181B1/ko not_active Expired - Fee Related
- 1999-02-16 DE DE69939605T patent/DE69939605D1/de not_active Expired - Lifetime
- 1999-02-16 ID IDW20001870A patent/ID26022A/id unknown
- 1999-02-16 US US09/622,663 patent/US6426087B1/en not_active Expired - Lifetime
- 1999-02-16 HU HU0100970A patent/HU226732B1/hu not_active IP Right Cessation
- 1999-02-16 PL PL377398A patent/PL201851B1/pl unknown
- 1999-02-16 SK SK5107-2005A patent/SK286248B6/sk not_active IP Right Cessation
- 1999-02-16 CZ CZ20002940A patent/CZ299366B6/cs not_active IP Right Cessation
- 1999-02-16 PT PT99913165T patent/PT1056445E/pt unknown
- 1999-02-16 DE DE69917750T patent/DE69917750T2/de not_active Expired - Lifetime
- 1999-02-16 SI SI9930637T patent/SI1056445T1/xx unknown
- 1999-02-22 ZA ZA9901408A patent/ZA991408B/xx unknown
- 1999-02-23 AR ARP990100731A patent/AR018109A1/es active IP Right Grant
-
2000
- 2000-08-22 NO NO20004190A patent/NO20004190L/no not_active Application Discontinuation
- 2000-08-22 OA OA1200000231A patent/OA11454A/en unknown
-
2002
- 2002-03-19 US US10/100,084 patent/US6514524B1/en not_active Expired - Lifetime
-
2008
- 2008-06-04 AR ARP080102354A patent/AR066843A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066843A2 (es) | Formulacion galenica administrable por via oral que permite una absorcion mejorada de principios activos, uso de un agente mejorador de la absorcion para preparar una forma de dosificacion administrable por via oral y procedimiento para preparar dicha formulacion galenica | |
| ES2539861T3 (es) | Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos | |
| ATE497384T1 (de) | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen | |
| CA2072509A1 (en) | Cyclosporin emulsion compositions for oral administration | |
| IT1247529B (it) | Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale | |
| ES2110377T1 (es) | Formulacion galenica de fenofibrato y aplicacion de la misma. | |
| PE20020307A1 (es) | Forma de dosificacion de farmaco activada por hidrogel | |
| AR013117A1 (es) | Una composicion farmaceutica solida en forma de comprimido que comprende un derivado de benzofurano con actividad antiarritmica adaptada para administracion oral | |
| ES2093269T3 (es) | Microemulsiones del tipo agua en aceite. | |
| DK0750495T3 (da) | Anvendelse af et lipofilt overfladeaktivt middel i et farmaceutisk præparat | |
| AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
| ES2065178T3 (es) | Dispositivo osmotico para el suministro retardado de un agente. | |
| CO5160287A1 (es) | Formulacion de liberacion controlada de divalproex sodico | |
| DE69414840D1 (de) | Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff | |
| ES2113444T3 (es) | Medicamentos. | |
| AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
| RU2000131897A (ru) | Пероральная дозировочная композиция пролонгированного действия | |
| AR030253A1 (es) | Sistemas de suministro de drogas autoemulsionantes para drogas lipofilicas extremadamente insolubles en agua, una formulacion y el uso de una composicion para la fabricacion de un medicamento | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| SE0102843L (sv) | Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod | |
| RU2002122744A (ru) | Новая самоэмульгирующаяся система доставки лекарств | |
| ATE301989T1 (de) | Orale pharmazeutische zusammensetzung mit einem wirkstoff, der bei seiner ersten darmpassage starken wirkungen ausgesetzt werden kann | |
| ES2546847T3 (es) | Formulaciones de un inhibidor de la Src/Abl | |
| AR011919A1 (es) | FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA | |
| MX9204382A (es) | Composiciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |